CytoSorbents Corporation — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual report, not a standalone fourth-quarter filing. Financial comparisons are with FY2013.
Business context
CytoSorbents develops blood-purification medical devices intended to remove inflammatory mediators and other toxins. Its lead product, CytoSorb, had EU CE Mark approval for cytokine removal and was being commercialized in Europe and through distributors. Other platforms, including HemoDefend, ContrastSorb, DrugSorb and BetaSorb, remained in development. The company was still loss-making and investing in commercialization, research and clinical studies.
Financial performance and liquidity
| Metric | FY2014 / Dec. 31, 2014 | FY2013 / Dec. 31, 2013 |
|---|---|---|
| Total revenue | $4.123 million | $2.423 million |
| Product sales | $3.135 million | $0.822 million |
| Grant income | $0.978 million | $1.601 million |
| Gross profit | $1.989 million | $0.511 million |
| Operating expenses | $9.268 million | $5.224 million |
| Loss from operations | $(7.279) million | $(4.713) million |
| Net loss | $(9.322) million | $(4.678) million |
| Net loss available to common shareholders | $(18.588) million | $(7.073) million |
| Net cash used in operating activities | $(6.661) million | $(3.489) million |
| Cash and cash equivalents | $3.605 million | $2.183 million |
| Short-term investments | $1.945 million | None reported |
| Current assets / current liabilities | $7.607 million / $4.505 million | $3.487 million / $3.065 million |
Revenue rose 70%, led by a 281% increase in product sales; management attributed growth to direct sales and distributor expansion. Product gross margin improved to approximately 63% from 61%. Total-company gross margin was approximately 48% versus 21%, reflecting the mix of product and grant revenue and costs. Grant income declined as several grants concluded.
Operating expenses increased substantially, including R&D of $2.432 million versus $1.739 million and selling, general and administrative expense of $5.551 million versus $2.577 million. Management cited hiring and European sales expansion, clinical studies, and NASDAQ-listing costs. Net loss also included a $2.118 million warrant-liability remeasurement expense, primarily associated with the increase in the company’s share price; this was a non-cash accounting item. Preferred-stock dividends of $9.267 million drove the larger loss available to common shareholders.
Cash flow from investing activities was $(2.312) million, including purchases of short-term investments; financing activities provided $10.017 million, principally from the 2014 equity offering. At year-end, the balance sheet showed a $2.981 million warrant liability and no convertible notes payable; the notes outstanding in 2013 had converted to common stock during 2014. No material conventional long-term debt balance is reported in the provided statements.
Material changes and significant events
- In March 2014, the company raised $10.2 million gross through an equity offering of common shares and warrants; reported net proceeds were approximately $9.451 million.
- In October 2014, Series A and Series B preferred stockholders converted their holdings. No Series A or Series B preferred shares remained outstanding at year-end. The conversions and related preferred dividends materially affected the equity presentation and loss attributable to common shareholders.
- In December 2014, the company completed a 25-for-1 reverse stock split, changed its state of incorporation from Nevada to Delaware, and began trading on the NASDAQ Capital Market under ticker CTSO.
- In January 2015, after the reporting date, the company raised $10.313 million gross in a public offering and reported approximately $9.409 million of net proceeds. The filing describes the proceeds as intended for clinical studies, production capacity, sales and marketing, product development, and working capital.
- In February 2015, the FDA authorized a planned 20-patient U.S. cardiac-surgery feasibility study under an IDE. This is permission to conduct an investigational study, not FDA marketing approval.
Outlook, commentary and risks
Management said year-end cash and investments, together with the January 2015 offering, were expected to fund operations into 2016. It also cautioned that additional capital might be needed for pivotal U.S. and/or German trials; the funding need would depend on finalized study protocols. The filing gives no formal revenue, earnings or cash-flow guidance.
The auditor’s report and the filing state that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Management believed funding was adequate for more than the next twelve months, but expected continuing losses and acknowledged possible future financing needs.
- Clinical evidence remains limited: the European Sepsis Trial’s 43 electronically randomized patients showed cytokine reductions, while reported mortality benefits came from post-hoc subgroups with small sample sizes. The filing says larger prospective studies are needed to confirm those findings; an earlier manual-randomization cohort had enrollment imbalance.
- CytoSorb had EU approval, but U.S. commercialization and approvals in other jurisdictions were not assured. Registration timing, clinical evidence, reimbursement and physician adoption could delay or limit sales. CytoSorb was reimbursed in Germany and Austria; reimbursement elsewhere was not assured.
- Sales expansion, product manufacturing scale-up, foreign-exchange movements and reliance on distributors and government research contracts could affect results. The company reported a $367,000 increase in foreign-exchange losses within SG&A.
- The company cited competitive, product-liability, intellectual-property and dilution risks. It reported 32 issued U.S. patents, but patent validity and breadth are not guaranteed; royalties apply to certain products. It also described potential future disputes involving Dow patents. No current legal proceedings were reported.
- CytoSorbents reported no outstanding preferred stock at year-end, but its charter authorized additional common and blank-check preferred shares. The 2014 offering included warrants, and the filing disclosed substantial outstanding options and warrants.
Important facts for investors to verify
- Reconcile reported year-end liquidity and subsequent financing, including the exact net proceeds of the January 2015 offering and cash runway assumptions.
- Review the audited cash-flow statement, going-concern language and the timing and cost of planned pivotal trials.
- Assess whether product-sales growth and gross margins can continue as grant income declines and commercialization expenses rise.
- Examine the design, enrollment, endpoints and full results of the sepsis and cardiac-surgery studies, distinguishing exploratory findings from prospective evidence.
- Confirm regulatory and reimbursement status by country, and track distributor registrations, actual purchases and repeat use.
- Evaluate potential dilution from outstanding options and warrants, future capital needs, and the effects of the reverse split and preferred-stock conversions.